Avalon Pharmaceuticals to Present at BIO CEO & Investor Conference
February 06 2008 - 11:35AM
Business Wire
Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that
Kenneth C. Carter, Ph.D., President and CEO, will provide an update
on the Company at the BIO CEO & Investor Conference. The
conference will be held at the Waldorf-Astoria Hotel in New York
from February 11-13. Dr. Carter is scheduled to present on Monday,
February 11, at 3:30pm. The presentation will be available live via
webcast and can be accessed through the Investor Presentations
section of Avalon Pharmaceuticals� website,
http://www.avalonrx.com, or go directly to the webcast via the
following URL:
http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=AVRX&item_
id=1752233. (Due to its length, this URL may need to be
copied/pasted into your Internet browser's address field. Remove
the extra space if one exists.) An archive of the presentation will
be available for 90 days following the conference. About Avalon
Pharmaceuticals Avalon is a biopharmaceutical company focused on
the discovery, development and commercialization of first-in-class
cancer therapeutics. Avalon�s lead product candidate, AVN944,�an
IMPDH inhibitor, is in Phase II clinical development. Avalon also
has preclinical programs to develop inhibitors of the Beta-catenin
and Aurora/Centrosome pathways,�discovery programs�for�inhibitors
of�the Survivin�and Myc�pathways and partnerships with Merck,
MedImmune, ChemDiv, Medarex, and Novartis. AvalonRx� is the
company�s proprietary platform�which is based
on�large-scale�biomarker identification and monitoring, used to
discover and develop therapeutics for pathways that have
historically been characterized as "undruggable." Avalon is
headquartered in Germantown, MD. Safe Harbor Statement This
announcement contains, in addition to historical information,
certain forward-looking statements that involve risks and
uncertainties. Such statements reflect the current views of Avalon
management and are based on certain assumptions. Actual results
could differ materially from those currently anticipated as a
result of a number of factors, risks and uncertainties, including
those specified under the �Risk Factors� section of our 2006 Annual
Report on Form 10-K and updates contained in subsequent filings we
make with the Securities and Exchange Commission.
Avalon (NASDAQ:AVRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avalon (NASDAQ:AVRX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Avalon Pharmaceuticals (MM) (NASDAQ): 0 recent articles
More Avalon Pharmaceuticals, Inc. News Articles